---
title: "Hormone-receptor positive (HER2 negative)-of-metastatic breast cancer"
slug: "hormone-receptor-positive-her-negative-of-metastatic-breast-cancer"
date: "2023-12-06 15:57:58"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[metastatic breast cancer]]

# Hormone-receptor positive (HER2 negative)-of-metastatic breast cancer

Tx paradigm: Serial endocrine therapy Â± targeted agents until failure â†’ chemo (start w/ chemo if visceral crisis or rapid POD)

## Endocrine therapy

### 1st line

- ET + [[CDK4_6i]] (AI + palbociclib, abemaciclib, ribociclib all w/ similar PFS benefit (HR 0.48 to 0.55), OS maturing.
- See Table below for tox
  - ([[PALOMA-2]], NEJM 2016;375:1925; MONALEESA-2, Ann Oncol 2018;29:1541; MONARCH 3, JCO 2019;5:5)
- If premenopausal, OFS + AI + CDK4/6.
  - Ribociclib vs. placebo + ET (tam/AI+OFS) showed â†‘ PFS, OS (MONALEESA-7, Lancet 2018;19:904)
- Fulvestrant + ribociclib (MONALEESA-3, NEJM 2020;382:514)
  - (especially if met <12 mos on adj. AI) vs. fulvestrant + AI vs. single agent ET

### 2nd line or later

- [[Fulvestrant]] + CDK4/6i (if not received 1st line)
  - [[PALOMA-3]], NEJM 2018;379:1926; å¤š5å€‹æœˆ
  - [[MONALEESA-3]], NEJM 2020;382:514; 29:1541; as 1L or 2L
  - [[MONARCH 2]], JAMA Onc 2019;6:116
- If PIK3CA mut:
  - [[Fulvestrant]] + alpelisib-â†‘ PFS (SOLAR1, NEJM 2019;380:1929)
  - Requires monitoring for hyperglycemia, stomatitis, rash, diarrhea
- [[Everolimus]] + [[exemestane]]:
  - â†‘ PFS (BOLERO-2, NEJM 2012;366:520)
- [[Abemaciclib]] single agent:
  - Clinical benefit rate of 42%
  - MONARCH-1, CCR 2017;23:5218
- Single agent ET in case of elderly or poor KPS pts

## Chemo (same paradigm as in TNBC section below), but favor cape if gradual pace of progression

- [[Triple negative disease]]

## Therapies under development

- Oral SERD (multiple in development),
- PI3K delta-selective inhibitors,
- AKTi,
- CDK2/4/6 inhibitor

### Siblings

- [[Workup-of-metastatic breast cancer]]
- [[General management principles-of-metastatic breast cancer]]
- [[Hormone-receptor positive (HER2 negative)-of-metastatic breast cancer]]
- [[HER2 positive-of-metastatic breast cancer]]
- [[Triple negative disease]]
- [[Bone metastasis]]
